ShockWave’s disruptive approach within the calcified cardiovascular disease space creates a first-mover advantage offering the opportunity of robust sales growth. ShockWave Medical’s business model ...
ATLANTA, May 19, 2021 /PRNewswire/ -- SoftWave Tissue Regeneration Technologies patented extracorporeal shock wave device called the OrthGold 100® was cleared by the FDA on May 4, 2021, for the ...
As an adjunct to bypass surgery for ischemic cardiomyopathy, a cardiac shockwave therapy aimed at regenerating ischemic myocardium boosted left ventricular ejection fraction (LVEF) and physical ...
DUBLIN, Dec. 18, 2020 /PRNewswire/ -- The "Extracorporeal Shockwave Device Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Application" report has ...
The FDA on Dec. 28 permitted the marketing of Sanuwave’s Dermapace System to treat adults with diabetic foot ulcers. Here are three things to know. 1. The Dermapace System is an external shock wave ...
Shockwave will purchase outstanding Neovasc shares for $27.25 each, valuing the company at around $100 million, according to a Jan. 17 news release from Shockwave. Neovasc specializes in the treatment ...
SANTA CLARA, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified ...
Sanuwave Inc. finally won de novo approval for its Dermapace diabetic foot ulcer treatment technology after years of struggling to get the device to the U.S. market. The Alpharetta, Ga.-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback